Free Trial
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics logo
$14.30 +1.20 (+9.16%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$14.43 +0.13 (+0.90%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About 10x Genomics Stock (NASDAQ:TXG)

Key Stats

Today's Range
$13.11
$14.30
50-Day Range
$10.56
$14.64
52-Week Range
$6.78
$24.76
Volume
3.45 million shs
Average Volume
3.40 million shs
Market Capitalization
$1.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.54
Consensus Rating
Hold

Company Overview

10x Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

TXG MarketRank™: 

10x Genomics scored higher than 72% of companies evaluated by MarketBeat, and ranked 241st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    10x Genomics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 10x Genomics' stock forecast and price target.
  • Earnings Growth

    Earnings for 10x Genomics are expected to grow in the coming year, from ($1.43) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 10x Genomics is -20.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 10x Genomics is -20.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    10x Genomics has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about 10x Genomics' valuation and earnings.
  • Percentage of Shares Shorted

    12.96% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 10x Genomics has recently increased by 1.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    10x Genomics does not currently pay a dividend.

  • Dividend Growth

    10x Genomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.96% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 10x Genomics has recently increased by 1.40%, indicating that investor sentiment is decreasing.
  • News Sentiment

    10x Genomics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for 10x Genomics this week, compared to 7 articles on an average week.
  • Search Interest

    13 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 10x Genomics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.39% of the stock of 10x Genomics is held by insiders.

  • Percentage Held by Institutions

    84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 10x Genomics' insider trading history.
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Stock News Headlines

3 Reasons TXG is Risky and 1 Stock to Buy Instead
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
2 Growth Stocks Cathie Wood Is Buying Non-Stop
See More Headlines

TXG Stock Analysis - Frequently Asked Questions

10x Genomics' stock was trading at $14.36 at the beginning of the year. Since then, TXG shares have decreased by 0.4% and is now trading at $14.30.

10x Genomics (NASDAQ:TXG) released its earnings results on Thursday, August, 7th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics's revenue for the quarter was up 12.9% on a year-over-year basis.
Read the conference call transcript
.

10x Genomics (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Top institutional shareholders of 10x Genomics include ARK Investment Management LLC (11.28%), Sumitomo Mitsui Trust Group Inc. (4.89%), Nikko Asset Management Americas Inc. (4.88%) and AQR Capital Management LLC (3.36%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo.
View institutional ownership trends
.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/07/2025
Today
8/22/2025
Next Earnings (Estimated)
10/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TXG
CIK
1770787
Fax
N/A
Employees
1,240
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$6.50
Potential Upside/Downside
-5.3%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$182.63 million
Net Margins
-13.13%
Pretax Margin
-12.31%
Return on Equity
-12.88%
Return on Assets
-10.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.84
Quick Ratio
5.23

Sales & Book Value

Annual Sales
$610.78 million
Price / Sales
2.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.21 per share
Price / Book
2.30

Miscellaneous

Outstanding Shares
124,490,000
Free Float
112,800,000
Market Cap
$1.78 billion
Optionable
Optionable
Beta
2.03

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TXG) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners